New Healthcare market report from Business Monitor International: "Cambodia Pharmaceuticals & Healthcare Report Q1 2013"
Boston, MA -- (SBWIRE) -- 03/18/2013 -- BMI View: Rampant corruption will continue to be one of the key factors hindering the development of the pharmaceutical and healthcare sectors in Cambodia. In addition, improving conditions in neighbouring countries such as Vietnam and Thailand mean Cambodia will be seen as relatively unattractive to investors, which does not help in the advancement of these sectors.
Headline Expenditure Projections
- Pharmaceuticals: KHR651.8bn (US$161mn) in 2011 to KHR723.3bn (US$173mn) in 2012; +11% in local currency terms and +7.7% in US dollar terms. Growth forecast downgraded due to lower than expected pharmaceutical trade imports.
- Healthcare: KHR2,982bn (US$737mn) in 2011 to KHR3,312bn (US$794mn) in 2012; +11.1% in local currency terms and +7.8% in US dollar terms. Forecast unchanged from Q412.
- Medical Devices: KHR107.5bn (US$27mn) in 2011 to KHR118.1bn (US$28mn) in 2011; +9.8% in local currency terms and +6.6% in US dollar terms. Forecast unchanged from Q412.
View Full Report Details and Table of Contents
Risk/Reward Rating: Cambodia continues to rank last out of the 18 key markets in BMI's Q113 Asia Pacific Pharmaceutical Risk/Reward Ratings due to its lack of commitment to healthcare and perceived corruption in the country. It has a score of 33.5, significantly lower than the region's average of 53.4.
Key Trends And Developments
- In November 2012, a report issued by the National Center for Parasitology, Entomology and Malaria Control stated that dengue fever accounted for 170 child deaths in Cambodia in 10M12, up 154% from 67 fatalities in 10M11. Cambodia registered 39,290 dengue fever cases from January-October 2012, a 163% year-on-year increase up from 14,918 cases.
- In the same month, the UN-backed Global Fund to fight AIDS, tuberculosis and malaria accused Cambodia of 'serious' corruption in the use of funds intended to combat these diseases. Cambodia Health Minister Mam Bunheng stated that he had no knowledge of the corruption claims.
- In October 2012, the World Health Organization stated that the country has had significant success in the fight against tuberculosis (TB) in the last decade due to new universal care access to patients at primary health centres. The country, which has halved the number of new TB cases in the last decade, had one of the highest TB rates in the world 20 years ago. A survey in 2011 found TB prevalence declined from more than 1,500 cases per 100,000 people in 2002 to 820 in 2011, a reduction in prevalence of 40%. The country was able to achieve success due to the implementation of the WHO-recommended directly observed therapy, short course.
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Nigeria Pharmaceuticals & Healthcare Report Q1 2013
- Sweden Pharmaceuticals & Healthcare Report Q1 2013
- Bulgaria Pharmaceuticals & Healthcare Report Q1 2013
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2011
- Lithuania Pharmaceuticals & Healthcare Report Q1 2013
- Egypt Pharmaceuticals & Healthcare Report Q1 2013
- Slovenia Pharmaceuticals & Healthcare Report Q1 2013
- Morocco Pharmaceuticals & Healthcare Report Q1 2013
- Kuwait Pharmaceuticals & Healthcare Report Q1 2013
- Bangladesh Pharmaceuticals & Healthcare Report Q1 2013
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)